{
    "organizations": [],
    "uuid": "ae70d9b940283a902394a013a7f79a20eccf6649",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mylan-receives-tentative-approval/brief-mylan-receives-tentative-approval-for-combination-hiv-treatment-dtg-ftc-taf-under-fdas-pepfar-program-idUSASB0C6D8",
    "ord_in_thread": 0,
    "title": "BRIEF-Mylan Receives Tentative Approval For Combination HIV Treatment DTG/FTC/TAF Under FDA's Pepfar Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Mylan Nv:\n* MYLAN RECEIVES TENTATIVE APPROVAL FOR COMBINATION HIV TREATMENT DTG/FTC/TAF UNDER FDA‘S PEPFAR PROGRAM\n* MYLAN NV - ‍ ANTIRETROVIRAL WILL BE IMMEDIATELY AVAILABLE IN DEVELOPING COUNTRIES AS A FIRST-LINE REGIMEN FOR PEOPLE BEING TREATED FOR HIV/AIDS​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-20T20:53:00.000+02:00",
    "crawled": "2018-02-21T21:40:45.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "mylan",
        "nv",
        "mylan",
        "receives",
        "tentative",
        "approval",
        "combination",
        "hiv",
        "treatment",
        "fda",
        "pepfar",
        "program",
        "mylan",
        "nv",
        "antiretroviral",
        "immediately",
        "available",
        "developing",
        "country",
        "regimen",
        "people",
        "treated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}